Study name and who is eligible
AbbVie ABROAD (Phase 2)
WA only
ABBV-552 is a modulator of synaptic vesicle glycoprotein 2A (SV2A), which is a protein expressed in virtually all synapses in the brain and known to play a role in regulating neurotransmitter release. Given that synaptic loss is the major neurobiological correlate of cognitive deficits of Alzheimer’s disease, ABBV-552, through direct modulation of synaptic function, is expected to improve cognitive performance.
Who can be involved:
- Male or female, aged 50 – 90 years inclusive, at the time of informed consent
- Must be diagnosed with MCI or mild Alzheimer’s disease
- Has an identified, reliable, study partner
- If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening
What is involved:
- Week 1, 2, 6, 12, safety follow up (7 site visits) + 4 telephone call visits
- 3 months trial duration
- Oral tablet once a day
- Must be able to tolerate MRI scans
- 25% chance of receiving placebo
For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on a placebo medication
AU-ARROW
WA only
Research has shown that lifestyle modifications that include adopting a healthy diet, carrying out regular aerobic and resistance physical exercise, staying socially active, and undergoing brain training exercises can improve brain function and reduce the risk of dementia.
These results have inspired a world-wide research initiative for dementia risk reduction known as World-Wide FINGERS (WW-FINGERS). Australia has joined this initiative and will run the AUstralian multidomain Approach to Reduce dementia Risk by prOtecting brain health With lifestyle intervention study (AU-ARROW).
The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) – has shown that lifestyle modifications that include adopting a healthy diet, carrying out regular aerobic and resistance physical exercise, staying socially active, and undergoing brain training exercises can improve brain function and reduce the risk of dementia.
Who can be involved:
- 55-79 years of age
- Sedentary lifestyle
- Average diet
- Normal memory & thinking abilities
- Live within 15km’s of one of our gym locations (Carine, Nedlands, South Perth, Willagee & Canning Vale)
What is involved:
- 2 years trial duration
- Information sessions
- Must be willing to undergo blood tests
- Must be willing to undergo memory assessments
- Must be willing to wear a free Fitbit tracker
The study will last for two years and involves attending information sessions, undergoing 6-monthly blood tests and memory assessments, and wearing a free Fitbit tracker.
In the study, we will encourage you to adopt some healthy lifestyle changes including regular exercise, and if you are allocated to the intervention group, you will need to commit 5-8 hours a week for all of the lifestyle changes, for the two years of the study. If you are interested in FREE detailed health assessments and preventing cognitive decline through lifestyle please contact the AU-ARROW team at 08 6304 3966
* Please note that participants in this study may have a chance of being placed in either a multidomain intervention group or an education group.
ADNET
Australia wide
Cutting-edge, cost-free specialist diagnostics
The Australian Dementia Network (ADNeT) Screening and Trials initiative is creating opportunities for Australians living with Dementia to access new therapies under development by attracting major international dementia trials to Australia.
The initiative provides clinicians with cutting-edge specialist diagnostic techniques at no cost to the patient, with the aim of facilitating recruitment into intervention trials across Australia.
Eligible patients undergo amyloid PET brain imaging, MRIs and comprehensive and neuropsychological assessments. Results are provided to referring clinicians to assist with diagnosis and patient management.
Who can be involved:
- Male or female, aged 55 – 85 years inclusive, at the time of informed consent
- Must be diagnosed with mild-moderate cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s disease
- Has an identified, reliable, study partner
- Have no serious medical conditions
What is involved:
- Involves up to 5 study visits, repeated at 2 – yearly intervals
- Must be able to tolerate MRI and PET scans
- Must be willing to undergo blood tests
- Must be willing to undergo memory assessments
For further information please contact Mark Rodrigues, Clinical Trial Coordinator at Ph: 08 6457 0266 or Email: m.rodrigues@ecu.edu.au
GSK 219867 GSK4527226 (Phase 2)
WA only
GSK4527226 is a monocloncal antibody that binds to sortilin, a transmembrane receptor that is a regulator of progranulin (PGRN). PGRN is a secreted protein that is expressed in the brain that is associated with regulation of lysosomal function and neuroinflammation in Alzheimer’s disease. GSK4527226 has been shown to increase PGRN and hopes to reduce decline in neurological function in Alzheimer’s disease patients.
Who can be involved:
- Male or female, aged 50 – 85 years inclusive, at the time of informed consent
- Must be diagnosed with MCI or mild Alzheimer’s disease
- Has an identified, reliable, study partner
- If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening
What is involved:
- Visits: Every month for 18 months
- 24 months study duration including screening and follow up periods
- IV infusion once a month
- Must be able to tolerate MRI and PET scans
- 33% chance of receiving placebo
For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on a placebo medication
INmuneBio MINDFuL (Phase 2)
WA only
INmune Bio, Inc is developing XPro™ as a therapy for patients with mild to moderate Alzheimer’s disease who have elevated inflammatory markers in their blood. Researchers believe Alzheimer’s disease may be defined as an inflammatory condition of the brain. It is hoped that by preventing this inflammation pathway the symptoms of Alzheimer’s disease may be improved or stabilised. This drug has been thoroughly tested successfully in oncology patients.
Who can be involved:
- Male or female, aged 60 – 85 years inclusive, at the time of informed consent
- Must be diagnosed with mild Alzheimer’s disease
- Has an identified, reliable, study partner
- If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening
What is involved:
- Weekly/quarterly visits
- 6 months trial duration
- Weekly subcutaneous injection (home dosing or self-administration available)
- Must be able to tolerate MRI scans
- 33% chance of receiving a placebo
For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on a placebo medication.
EISAI AHEAD 3-45 BAN2401-G000-303 (Phase 3)
WA only
This is a Phase 3 study to test whether treatment with BAN2401, an anti-amyloid monoclonal antibody, prevents cognitive decline and reduces brain amyloid accumulation. The changes in the amount of amyloid by PET scans and tau in the brain will be monitored to determine the efficacy of the investigational medication.
Who can be involved:
- Male or female, aged 55 – 80 years inclusive, at the time of informed consent
- Must have risk factors for Alzheimer’s disease (first-degree relative but no formal diagnosis)
- Has an identified, reliable, study partner
- If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening
What is involved:
- Fortnightly / monthly visits
- 5 years trial duration
- Fortnightly / monthly IV infusion (fortnightly or monthly depending on your risk of Alzheimer’s disease)
- Must be able to tolerate MRI and PET scans
- 50% chance of receiving a placebo
For further information please contact Paula Mather, Clinical Trial Coordinator at Ph: (08) 9389 6433 or Email: aarfctd@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on placebo medication.
Biogen ENVISION (Phase 3b/4)
WA only
Aducanumab, the investigational drug of this trial, was approved by the US FDA as a treatment for Alzheimer’s disease in June 2021. Approval was based on evidence that aducanumab reduces brain amyloid, coupled with evidence that the reduction in amyloid identified in aducanumab clinical studies is reasonably likely to predict clinical benefit in Alzheimer’s disease. This study is being conducted to fulfil a post marketing requirement from the FDA to verify the clinical benefit of aducanumab.
Who can be involved:
- Male or female, aged 60 – 85 years inclusive, at the time of informed consent
- MCI or mild Alzheimer’s disease
- Has an identified, reliable, study partner
- If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening
What is involved:
- Monthly visits
- 5 years trial duration
- Monthly IV infusion
- Must be able to tolerate MRI and PET scans
- 33% chance of receiving a placebo
For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on a placebo medication.
Probucol in Alzheimer’s Study/PIA Study
The Study aims to determine whether Probucol is effective for slowing the decline in memory and thinking skills in people with MCI (mild cognitive impairment) or mild Alzheimer’s disease, as well as the impact of Probucol on amyloid protein. Probucol is an anti-hyperlipidemic drug initially developed for the treatment of cardiovascular disease. Recent research has shown that Probucol appears to decrease microscopic blood vessel inflammation and reduce exposure to potentially toxic proteins in the brain. These microscopic blood vessels are important for maintaining brain function, cognition, and memory.
Who can be involved:
- Male or female, aged 18-85 years, at the time of informed consent
- Must be diagnosed with mild-moderate cognitive impairment due to probable Alzheimer’s disease or mild Alzheimer’s disease
- Has an identified, reliable, study partner
If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months before screening
What is involved:
- Weekly visits for five weeks, then approximately every three months
- 2 years trial duration
- Daily medication twice a day (oral tablet)
- A positive amyloid result on a PET scan
For further information please contact the Clinical Trial Coordinator on Ph: 0468 532 458 or
Email: piastudy@curtin.edu.au
Please note that participants in this study may have a chance of being placed on a placebo medication.
Testosterone Study – (Phase 2)
NSW & WA only
This study aims to evaluate the impact of testosterone alone or in combination with fish oil on amyloid load in the brain, as well as whether it affects performance on tests of memory, cognition and function.
Who can be involved:
- Males aged between 60 to 80 years
- Does not have a current medical or neurological condition
- Not currently taking testosterone or diagnosed with hypogonadism
- Western Australia and New South Wales residents
What is involved:
- 18-month duration
- Most visits 8 weeks apart
- Testosterone/placebo will be administered intramuscularly every 8 weeks
- Medical examinations, memory tests and brain scans
For further information please contact
WA Contact: Anne McKinney, Study Coordinator on Ph: (08) 6304 3966 or Email: trial@alzheimers.com.au
NSW Contact: Anna Johnson, Clinical Trial Coordinator on Ph: (02) 9850 5713 or Email: trial@alzheimers.com.au
* Please note that participants in this study may have a chance of being placed on placebo medication.
Sleep Study
WA only
This study aims to examine whether improved sleep (better or longer) contributes to better memory and thinking, and improved markers of brain health (assessed using brain imaging). The study will implement a non-pharmacological intervention to improve sleep in older adults who are ‘poor sleepers’.
Who can be involved:
- Male and females aged 60 years to 80 years
- Residents from Western Australia
What is involved:
- Attend a sleep improvement program
- Have your sleep patterns measured
- Undergo assessments of memory and thinking
- Undergo brain imaging scans
For further information about the Sleep Study please contact Jo Shaw, Clinical Trial Coordinator at (08) 6457 0264 or email j.shaw@ecu.edu.au
